Friction reducers, fluid compositions and uses thereof
US-12054669-B2 · Aug 6, 2024 · US
US10214681B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10214681-B2 |
| Application number | US-201514676162-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 1, 2015 |
| Priority date | Apr 1, 2015 |
| Publication date | Feb 26, 2019 |
| Grant date | Feb 26, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method of treating a subterranean formation including combining an aqueous fluid, a biomaterial, an enzyme, and a deactivator to form a treatment fluid; and introducing the treatment fluid into the subterranean formation. A method is also disclosed for treating a subterranean formation by preparing a treatment fluid containing an aqueous fluid that contains bacterial and/or fungal cells that produce an enzyme that degrades the biomaterial, a biomaterial, and a deactivator; controlling degradation of the biomaterial by adding an effective amount of the deactivator to the aqueous fluid prior to the preparation of the treatment fluid; and introducing the treatment fluid into the subterranean formation. In the methods, the enzyme degrades the biomaterial and the deactivator is an oxygen-containing arene capable of inhibiting the enzyme from degrading the biomaterial.
Opening claim text (preview).
What is claimed is: 1. A method for treating a subterranean formation, the method comprising: combining an aqueous fluid, a biomaterial, an enzyme, and a deactivator to form a non-crosslinked treatment fluid; and introducing the non-crosslinked treatment fluid into the subterranean formation; wherein: the enzyme degrades the biomaterial; and the deactivator is an oxygen-containing arene capable of inhibiting the enzyme from degrading the biomaterial, wherein the deactivator comprises at least one of a naphthol, dimethoxybenzene, trimethoxybenzene, and a structure represented by wherein: R7 represents an alkyl group having about 1 to about 5 atoms optionally including one or more heteroatoms, and R3, R4, R5, and R6 each independently represents a hydrogen atom, a hydroxyl group, an alkyl group, an alkene group, an ester, a carboxylic acid, an alcohol, an aldehyde, a ketone, an aryl, an aryloxy, cycloalkyl, a carbonyl, or an amino group, wherein the non-crosslinked treatment fluid does not crosslink. 2. The method according to claim 1 , wherein at least a portion of the enzyme is produced by bacterial and/or fungal cells present in the aqueous fluid. 3. The method according to claim 1 , further comprising adjusting a viscosity of the treatment fluid to be a viscosity in a range of from about 10 cP to about 5,000 cP before introducing the treatment fluid into the subterranean formation. 4. The method according to claim 3 , wherein adjusting the viscosity of the treatment fluid comprises increasing an amount of the deactivator in the treatment fluid. 5. The method according to claim 4 , wherein the amount of the deactivator in the treatment fluid is increased to an amount in a range of from about 0.005 g/L to about 15 g/L. 6. The method according to claim 1 , wherein the enzyme is selected from a group consisting of mannanase, glucosidase, cellulase, amylase, hydrolase, and glucanase. 7. The method according to claim 1 , wherein the deactivator is selected from a group consisting of dihydroxy-methoxybenzene, dihydroxy-dimethoxybenzene, liginsulfonate, 1 amino-2-naphthol, 2-amino-1-naphthol, 3-amino-2-naphthol, 4-amino-1-naphthol, 8-amino-1-naphthol, 5-amino-1-naphthol, 1,2-dimethoxybenzene, 1,3-dimethoxybenzene, 1,2,3-trimethoxybenzene, 1,2,4-trimethoxybenzene, 1,2,5-trimethoxybenzene, 1,2,6-trimethoxybenzene, and 1,3,5-trimethoxybenzene, 1,3-benzodioxole, benzo-1,4,-dioxane, 2,3-dihydro-1,4,-benzodioxin-5-ol, 5-methoxy-1,3-benzodioxole, 5,6-dihydroxy-1,3-benzodioxole, sesamol, 5-methyl-1,3-benzodioxole, sesamin, piperonyl alcohol, piperonal, and 3,4-methylenedioxy aniline, 1,8-dihydroxynaphthalene, 1,5-dihydroxynaphthalene, 2,3-dihydroxynaphthalene, 2,7-dihydroxynaphthalene, 1,7-dihydroxynaphthalene, and 2,6-dihydroxynaphthalene. 8. The method according to claim 1 , wherein the biomaterial is selected from a group consisting of guar gum, locust bean gum, tara gum, honey locust gum, tamarind gum, karaya gum, arabic gum, ghatti gum, tragacanth gum, carrageenan, succinoglycan, xanthan, diutan, alginate, hydroxylethyl guar, hydroxypropyl guar, carboxymethylhydroxypropyl guar, carboxymethyl cellulose, carboxyethyl cellulose, carboxymethyl guar, carboxymethylhydroxyethyl cellulose, and combinations thereof. 9. The method according to claim 2 , wherein prior to forming the treatment fluid, the method further comprises measuring an amount of the bacterial and/or fungal cells in the aqueous fluid. 10. The method according to claim 9 , further comprising: determining an effective amount of the deactivator for controlling a viscosity of the treatment fluid to be in a range of from about 10 cP to about 5,000 cP based on the measurement of the amount of bacterial and/or fungal cells present in the aqueous fluid; and combining the effective amount of the deactivator with the aqueous fluid, the biomaterial, and the enzyme. 11. The method according to claim 1 , wherein the treatment fluid further comprises proppant particles. 12. A method for treating a subterranean formation, the method comprising: preparing a non-crosslinked treatment fluid comprising an aqueous fluid, a biomaterial, and a deactivator; controlling degradation of the biomaterial by adding an effective amount of the deactivator to the aqueous fluid prior to the preparation of the treatment fluid; and introducing the non-crosslinked treatment fluid into the subterranean formation; wherein: the aqueous fluid comprises bacterial and/or fungal cells that produce an enzyme that degrades the biomaterial; the deactivator is an oxygen-containing arene capable of inhibiting the enzyme from degrading the biomaterial, the deactivator comprising at least one of a naphthol, dimethoxybenzene, trimethoxybenzene, and a structure represented by where: R7 represents an alkyl group having about 1 to about 5 atoms optionally including one or more heteroatoms; and R3, R4, R5, and R6 each independently represents a hydrogen atom, a hydroxyl group, an alkyl group, an alkene group, an ester, a carboxylic acid, an alcohol, an aldehyde, a ketone, an aryl, an aryloxy, cycloalkyl, a carbonyl, or an amino group, wherein the non-crosslinked treatment fluid does not crosslink. 13. The method according to claim 12 , wherein a viscosity of the treatment fluid is in a range of from about 10 cP to about 5,000 cP before introducing the treatment fluid into the subterranean formation. 14. The method according to claim 12 , wherein the enzyme is selected from a group consisting of mannanase, glucosidase, cellulase, amylase, hydrolase, and glucanase. 15. The method according to claim 12 , wherein the effective amount of the deactivator is an amount in a range of from about 0.005 g/L to about 15 g/L. 16. The method according to claim 12 , wherein the deactivator is selected from a group consisting of dihydroxy-methoxybenzene, dihydroxy-dimethoxybenzene, liginsulfonate, 1 amino-2-naphthol, 2-amino-1-naphthol, 3-amino-2-nahthol, 4-amino-1-naphthol, 8-amino-1-naphthol, 5-amino-1-naphthol, 1,2-dimethoxybenzene, 1,3-dimethoxybenzene, 1,2,3-trimethoxybenzene, 1,2,4-trimethoxybenzene, 1,2,5-trimethoxybenzene, 1,2,6-trimethoxybenzene, and 1,3,5-trimethoxybenzene, 1,3-benzodioxole, benzo-1,4,-dioxane, 2,3-dihydro-1,4,-benzodioxin-5-ol, 5-methoxy-1,3-benzodioxole, 5,6-dihydroxy-1,3-benzodioxole, sesamol, 5-methyl-1,3-benzodioxole, sesamin, piperonyl alcohol, piperonal, and 3,4-methylenedioxy aniline, 1,8-dihydroxynaphthalene, 1,5-dihydroxynaphthalene, 2,3-dihydroxynaphthalene, 2,7-dihydroxynaphthalene, 1,7-dihydroxynaphthalene, and 2,6-dihydroxynaphthalene. 17. The method according to claim 12 , wherein the biomaterial is selected from a group consisting of guar gum, locust bean gum, tara gum, honey locust gum, tamarind gum, karaya gum, arabic gum, ghatti gum, tragacanth gum, carrageenan, succinoglycan, xanthan, diutan, alginate, hydroxylethyl guar, hydroxypropyl guar, carboxymethylhydroxypropyl guar, carboxymethyl cellulose, carboxyethyl cellulose, carboxymethyl guar, carboxymethylhydroxyethyl cellulose, and combinations thereof.
containing cross-linking agents · CPC title
containing organic compounds · CPC title
Bacteria or enzyme containing gel breakers · CPC title
Biopolymers · CPC title
containing cross-linking agents · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.